MX352962B - Compuestos para tratar atrofia muscular espinal. - Google Patents
Compuestos para tratar atrofia muscular espinal.Info
- Publication number
- MX352962B MX352962B MX2014010406A MX2014010406A MX352962B MX 352962 B MX352962 B MX 352962B MX 2014010406 A MX2014010406 A MX 2014010406A MX 2014010406 A MX2014010406 A MX 2014010406A MX 352962 B MX352962 B MX 352962B
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- muscular atrophy
- spinal muscular
- treating spinal
- treating
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 208000002320 spinal muscular atrophy Diseases 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261605487P | 2012-03-01 | 2012-03-01 | |
| PCT/US2013/028131 WO2013130689A1 (en) | 2012-03-01 | 2013-02-28 | Compounds for treating spinal muscular atrophy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014010406A MX2014010406A (es) | 2015-03-10 |
| MX352962B true MX352962B (es) | 2017-12-15 |
Family
ID=49083256
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014010406A MX352962B (es) | 2012-03-01 | 2013-02-28 | Compuestos para tratar atrofia muscular espinal. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9371336B2 (enExample) |
| EP (1) | EP2819519B1 (enExample) |
| JP (1) | JP6092264B2 (enExample) |
| KR (1) | KR102099997B1 (enExample) |
| CN (1) | CN104302181B (enExample) |
| BR (1) | BR112014021531B1 (enExample) |
| CA (1) | CA2865957C (enExample) |
| EA (1) | EA029155B1 (enExample) |
| MX (1) | MX352962B (enExample) |
| WO (1) | WO2013130689A1 (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6193881B2 (ja) | 2011-12-30 | 2017-09-06 | ピーティーシー セラピューティクス， インコーポレイテッド | 脊髄性筋萎縮症を治療するための化合物 |
| CA2862084C (en) | 2012-01-26 | 2021-05-11 | Ptc Therapeutics, Inc. | 1h-isochromen-1-one derivatives and compositions thereof for treating spinal muscular atrophy |
| ES2697174T3 (es) | 2012-02-10 | 2019-01-22 | Ptc Therapeutics Inc | Compuestos para tratar atrofia muscular espinal |
| US9914722B2 (en) | 2012-03-23 | 2018-03-13 | Ptc Therapeutics, Inc. | Compounds for treating spinal muscular atrophy |
| WO2014102778A2 (en) * | 2012-12-24 | 2014-07-03 | Ramot At Tel-Aviv University Ltd. | Agents for treating genetic diseases resulting from nonsense mutations, and methods for identifying the same |
| CN105392790B (zh) | 2013-08-19 | 2019-04-19 | 豪夫迈·罗氏有限公司 | 4H-吡啶并[1,2-a]嘧啶-4-酮化合物制备用于预防或治疗癌症的药物的用途 |
| WO2015105657A1 (en) | 2013-12-19 | 2015-07-16 | Ptc Therapeutics, Inc. | Methods for modulating the amount of rna transcripts |
| US10668171B2 (en) | 2015-05-30 | 2020-06-02 | Ptc Therapeutics, Inc. | Methods for modulating RNA splicing |
| EP3133065A1 (en) | 2015-08-21 | 2017-02-22 | Merck Patent GmbH | Compounds for optically active devices |
| KR20220100719A (ko) | 2015-12-10 | 2022-07-15 | 피티씨 테라퓨틱스, 인크. | 헌팅턴병 치료 또는 개선을 위한 조성물 |
| CA3043755A1 (en) | 2016-11-28 | 2018-05-31 | Ptc Therapeutics, Inc. | Methods for modulating rna splicing |
| EP3363793A1 (en) | 2017-02-15 | 2018-08-22 | Merck Patent GmbH | Hydrophobic compounds for optically active devices |
| EP3363786A1 (en) | 2017-02-15 | 2018-08-22 | Merck Patent GmbH | Compounds for optically active devices |
| AU2018282154B2 (en) | 2017-06-05 | 2022-04-07 | Ptc Therapeutics, Inc. | Compounds for treating huntington's disease |
| KR20200017476A (ko) | 2017-06-14 | 2020-02-18 | 피티씨 테라퓨틱스, 인크. | Rna 스플라이싱의 변경 방법 |
| WO2019005993A1 (en) | 2017-06-28 | 2019-01-03 | Ptc Therapeutics, Inc. | METHODS OF TREATING HUNTINGTON'S DISEASE |
| CA3067591A1 (en) | 2017-06-28 | 2019-01-03 | Ptc Therapeutics, Inc. | Methods for treating huntington's disease |
| KR102636383B1 (ko) | 2017-08-04 | 2024-02-14 | 스카이호크 테라퓨틱스, 인코포레이티드 | 스플라이싱을 조절하는 방법 및 조성물 |
| AU2019243048A1 (en) | 2018-03-27 | 2020-10-15 | Ptc Therapeutics, Inc. | Compounds for treating Huntington's disease |
| CA3105174A1 (en) | 2018-06-27 | 2020-01-02 | Reborna Biosciences, Inc. | Prophylactic or therapeutic agent for spinal muscular atrophy |
| BR112020026534A2 (pt) | 2018-06-27 | 2021-03-23 | Ptc Therapeutics, Inc. | Compostos de heteroarila para o tratamento da doença de huntington |
| WO2020005882A1 (en) | 2018-06-27 | 2020-01-02 | Ptc Therapeutics, Inc. | Heteroaryl compounds for treating huntington's disease |
| IL279688B2 (en) | 2018-06-27 | 2025-01-01 | Ptc Therapeutics Inc | Heterocyclic and heteroaryl compounds for the treatment of Huntington's disease |
| CN119320388A (zh) | 2019-02-04 | 2025-01-17 | 斯基霍克疗法公司 | 用于调节剪接的方法和组合物 |
| JP7551629B2 (ja) | 2019-02-05 | 2024-09-17 | スカイホーク・セラピューティクス・インコーポレーテッド | スプライシングを調節するための方法および組成物 |
| KR102913697B1 (ko) | 2019-02-05 | 2026-01-15 | 스카이호크 테라퓨틱스, 인코포레이티드 | 스플라이싱을 조절하는 방법 및 조성물 |
| JP7603594B2 (ja) | 2019-02-06 | 2024-12-20 | スカイホーク・セラピューティクス・インコーポレーテッド | スプライシングを調節するための方法および組成物 |
| WO2020163544A1 (en) | 2019-02-06 | 2020-08-13 | Skyhawk Therapeutics, Inc. | Methods and compositions for modulating splicing |
| CN114245794B (zh) | 2019-05-13 | 2024-09-13 | Ptc医疗公司 | 用于治疗亨廷顿氏病的化合物 |
| US11129829B2 (en) | 2019-06-17 | 2021-09-28 | Skyhawk Therapeutics, Inc. | Methods for modulating splicing |
| CN111116460A (zh) * | 2019-12-31 | 2020-05-08 | 阿里生物新材料（常州）有限公司 | 一种2-氯-4-羟基吡啶-3-甲醛氢溴酸盐的合成方法 |
| JP7763397B2 (ja) | 2020-05-20 | 2025-11-04 | エイエムオー・アイルランド | 光学活性装置で使用するためのアザクマリン及びアザチオクマリン誘導体 |
| WO2023114539A1 (en) * | 2021-12-17 | 2023-06-22 | Pretzel Therapeutics, Inc. | Amino chromen-2-one modulators of polrmt |
| AU2024286618A1 (en) * | 2023-06-09 | 2025-10-30 | F. Hoffmann-La Roche Ag | Inducible gene expression system |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3558618A (en) | 1968-04-01 | 1971-01-26 | Dow Chemical Co | Novel 4h-pyrazino(1,2-a)pyrimidine-4-ones |
| US4122274A (en) | 1977-05-25 | 1978-10-24 | Bristol-Myers Company | 3-Tetrazolo-5,6,7,8-substituted-pyrido[1,2-a]pyrimidin-4-ones |
| US4342870A (en) | 1980-03-28 | 1982-08-03 | Janssen Pharmaceutica N.V. | Novel 3-(1-piperidinylalkyl)-4H-pyrido[1,2-a]pyrimidin-4-one derivatives |
| US5089633A (en) | 1987-04-28 | 1992-02-18 | Georgia Tech Research Corporation | Substituted isocoumarins |
| US5726182A (en) | 1990-05-02 | 1998-03-10 | Abbott Laboratories | Quinolizinone type compounds |
| AU4231293A (en) | 1992-05-13 | 1993-12-13 | E.I. Du Pont De Nemours And Company | Substituted pyrido(1,2-A)pyrimidinone derivatives as fungicides |
| US5597922A (en) * | 1994-07-29 | 1997-01-28 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon | Glycine receptor antagonist pharmacophore |
| US6630488B1 (en) | 1998-09-21 | 2003-10-07 | Biochem Pharma, Inc. | Quinolizinones as integrin inhibitors |
| EP1857443B1 (en) | 2000-01-24 | 2012-03-28 | AstraZeneca AB | Therapeutic morpholino-substituted compounds |
| GB0205281D0 (en) * | 2002-03-06 | 2002-04-17 | Novartis Ag | Organic compounds |
| US20040077529A1 (en) | 2002-06-10 | 2004-04-22 | Per-Fredrik Lehmann | Urotensin II receptor agents |
| AU2003298719A1 (en) | 2002-11-25 | 2004-06-18 | Antonia C. Kaloidis | Treatment for sma disease |
| US9068234B2 (en) | 2003-01-21 | 2015-06-30 | Ptc Therapeutics, Inc. | Methods and agents for screening for compounds capable of modulating gene expression |
| EP1636225B1 (en) | 2003-06-20 | 2010-02-24 | Novartis Vaccines and Diagnostics, Inc. | Pyridino 1,2-a pyrimidin-4-one compounds as anticancer agents |
| US20050046698A1 (en) * | 2003-09-02 | 2005-03-03 | Knight Andrew Frederick | System and method for producing a selectable view of an object space |
| EP1687002A4 (en) * | 2003-11-10 | 2008-07-23 | Synta Pharmaceuticals Corp | CONDENSED HETEROCYCLIC COMPOUNDS |
| DE602005002562T2 (de) | 2004-05-04 | 2008-01-31 | Warner-Lambert Company Llc | Pyrrolylsubstituierte pyridoä2,3-düpyrimidin-7-one und derivate davon als therapeutische mittel |
| CA2584485C (en) | 2004-10-20 | 2013-12-31 | Resverlogix Corp. | Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases |
| AU2006206446A1 (en) | 2005-01-21 | 2006-07-27 | Janssen Pharmaceutica N.V. | Novel heterocyclic benzo[c]chromene derivatives useful as modulators of the estrogen receptors |
| AR059339A1 (es) | 2006-02-09 | 2008-03-26 | Chugai Pharmaceutical Co Ltd | Derivados de la cumarina para trastornos proliferativos de celulas, composicion farmaceutica y agente terapeutico que los contiene |
| US8337941B2 (en) | 2006-07-27 | 2012-12-25 | The Trustees Of Columbia University In The City Of New York | Fluorescent substrates for monoamine transporters as optical false neurotransmitters |
| EP2573080A1 (en) * | 2007-09-27 | 2013-03-27 | The United States of America, as Represented by the Secretary, Department of Health and Human Services | Isoindoline compounds for the treatment of spinal muscular atrophy and other uses |
| WO2009151546A2 (en) * | 2008-05-27 | 2009-12-17 | Ptc Therapeutics, Inc. | Methods for treating spinal muscular atrophy |
| US8986935B2 (en) | 2008-08-13 | 2015-03-24 | Ptc Therapeutics, Inc. | Methods for treating spinal muscular atrophy |
| WO2011062853A1 (en) | 2009-11-20 | 2011-05-26 | Merck Sharp & Dohme Corp. | Quinolizidinone carboxamide m1 receptor positive allosteric modulators |
| AU2011206761A1 (en) | 2010-01-13 | 2012-07-12 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Anti - infective pyrido (1,2 -a) pyrimidines |
| JP6193881B2 (ja) | 2011-12-30 | 2017-09-06 | ピーティーシー セラピューティクス， インコーポレイテッド | 脊髄性筋萎縮症を治療するための化合物 |
| CA2862084C (en) | 2012-01-26 | 2021-05-11 | Ptc Therapeutics, Inc. | 1h-isochromen-1-one derivatives and compositions thereof for treating spinal muscular atrophy |
| ES2697174T3 (es) | 2012-02-10 | 2019-01-22 | Ptc Therapeutics Inc | Compuestos para tratar atrofia muscular espinal |
| US9914722B2 (en) | 2012-03-23 | 2018-03-13 | Ptc Therapeutics, Inc. | Compounds for treating spinal muscular atrophy |
-
2013
- 2013-02-28 KR KR1020147027577A patent/KR102099997B1/ko active Active
- 2013-02-28 BR BR112014021531-6A patent/BR112014021531B1/pt active IP Right Grant
- 2013-02-28 EP EP13755032.3A patent/EP2819519B1/en active Active
- 2013-02-28 EA EA201491617A patent/EA029155B1/ru not_active IP Right Cessation
- 2013-02-28 JP JP2014560007A patent/JP6092264B2/ja active Active
- 2013-02-28 WO PCT/US2013/028131 patent/WO2013130689A1/en not_active Ceased
- 2013-02-28 US US14/380,385 patent/US9371336B2/en active Active
- 2013-02-28 CA CA2865957A patent/CA2865957C/en active Active
- 2013-02-28 MX MX2014010406A patent/MX352962B/es active IP Right Grant
- 2013-02-28 CN CN201380023259.1A patent/CN104302181B/zh active Active
Also Published As
| Publication number | Publication date |
|---|---|
| HK1200056A1 (en) | 2015-07-31 |
| JP6092264B2 (ja) | 2017-03-08 |
| EA029155B1 (ru) | 2018-02-28 |
| JP2015509956A (ja) | 2015-04-02 |
| CA2865957A1 (en) | 2013-09-06 |
| BR112014021531A2 (pt) | 2017-06-20 |
| US9371336B2 (en) | 2016-06-21 |
| BR112014021531B1 (pt) | 2022-10-04 |
| US20150166575A1 (en) | 2015-06-18 |
| MX2014010406A (es) | 2015-03-10 |
| BR112014021531A8 (pt) | 2021-06-15 |
| WO2013130689A1 (en) | 2013-09-06 |
| KR20140131384A (ko) | 2014-11-12 |
| EP2819519A1 (en) | 2015-01-07 |
| CA2865957C (en) | 2020-02-11 |
| EA201491617A1 (ru) | 2015-01-30 |
| EP2819519B1 (en) | 2019-10-23 |
| CN104302181B (zh) | 2017-09-15 |
| KR102099997B1 (ko) | 2020-04-13 |
| CN104302181A (zh) | 2015-01-21 |
| EP2819519A4 (en) | 2015-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022011699A (es) | Compuestos para tratar la atrofia muscular espinal. | |
| MX357834B (es) | Compuestos de tipo isocumarina sustituidos para tratar la atrofia muscular espinal. | |
| MX2014010406A (es) | Compuestos para tratar atrofia muscular espinal. | |
| MX358514B (es) | Compuestos para tratar la atrofia muscular espinal. | |
| PH12014502704A1 (en) | Compounds and compositions for modulating egfr activity | |
| WO2014052836A3 (en) | Methods and compositions for treating infection | |
| GEP201706754B (en) | Proliposomal testosterone formulations | |
| MX359769B (es) | Metodos para descelularizar huesos. | |
| AU2013225816A8 (en) | Compositions and methods for treating Type III Gaucher Disease | |
| MX367393B (es) | Composiciones antifungicas para el tratamiento de piel y uñas. | |
| IL237542B (en) | Amphiphilic compounds, their preparations and uses | |
| WO2012017321A3 (en) | Treatment for dyslipidemia | |
| MX2013014488A (es) | Metodos y composiciones para tratar el cancer cerebral. | |
| IL237540B (en) | Amphiphilic compounds, their preparations and uses | |
| GEP201706708B (en) | Isoxazolidine derivatives | |
| MX356102B (es) | Compuestos y métodos para tratar leucemia. | |
| IL267888B (en) | Amphiphilic compounds, their preparations and uses | |
| IL237538B (en) | Amphiphilic compounds, their preparations and uses | |
| IL237539A0 (en) | Amphiphilic compounds, their preparations and uses | |
| MX2013008559A (es) | Derivados de leptina. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |